PolyPid - Public Comps and Valuation Multiples

PolyPid Overview

About PolyPid

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Founded

2008

HQ

Employees

Website

polypid.com

Sectors

Drug Development & Therapeutics
Drug Delivery Systems
BioTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$20.0M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

PolyPid Financials

PolyPid has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, PolyPid achieved revenue of n/a and an EBITDA of -$26.4M.

PolyPid expects next 12-month revenue of XXX and NTM EBITDA of XXX

See PolyPid valuation multiples based on analyst estimates

PolyPid P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	n/a	n/a	XXX	XXX	XXX
Gross Profit	n/a	n/a	XXX	XXX	XXX
Gross Margin	NaN%	NaN%	XXX	XXX	XXX
EBITDA	-$20.4M	-$26.4M	XXX	XXX	XXX
EBITDA Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Profit	-$39.6M	-$23.9M	XXX	XXX	XXX
Net Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Debt	$3.0M	$5.1M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

PolyPid Stock Performance

As of April 15, 2025, PolyPid's stock price is $3.

PolyPid has current market cap of $26.0M, and EV of $20.0M.

See PolyPid trading valuation data

PolyPid Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$20.0M	$26.0M	XXX	XXX	XXX	XXX	$-4.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

PolyPid Valuation Multiples

As of April 15, 2025, PolyPid has market cap of $26.0M and EV of $20.0M.

PolyPid's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate PolyPid's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for PolyPid and 10K+ public comps

PolyPid Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$20.0M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	-0.8x	XXX	XXX	XXX
P/E	-0.9x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-0.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PolyPid Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

PolyPid Valuation Multiples

PolyPid's NTM/LTM revenue growth is Infinity%

PolyPid's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.

Over next 12 months, PolyPid's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate PolyPid's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for PolyPid and other 10K+ public comps

PolyPid Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	30%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	$0.5M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
Opex to Revenue	n/a	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry